RxDoctor Payments Data

Kevin Saucier, MD

Pulmonary Disease · Mobile, ALNPI 1255317707

Payments from drug & device makers

$2,140in general payments, 2019–2025

Across 160 payments — averaging $13.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$705
  • Boehringer Ingelheim$534
  • AstraZeneca$212
  • Mylan Specialty L.p.$91
  • Philips North America LLC$77
  • Electromed, Inc.$75
  • plus $446 from 14 others

What the payments were for

  • Food & beverage$2,140100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,140 in reported general payments places this provider in the 40th percentile of 215 pulmonary disease providers in Alabama.

See all pulmonary disease providers in Alabama

Medicare billing

Part B allowed, 2024
$100,141
Medicare patients
263
Services billed
1,314

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter266$186,512
Breo ElliptaFluticasone/Vilanterol313$150,729
Fluticasone-SalmeterolFluticasone Propion/Salmeterol144$23,218
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr33$21,784
Albuterol Sulfate HfaAlbuterol Sulfate660$18,334
Combivent RespimatIpratropium/Albuterol Sulfate26$18,057
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$12,624
SymbicortBudesonide/Formoterol Fumarate34$11,291
Stiolto RespimatTiotropium Br/Olodaterol Hcl17$10,752
Ventolin HfaAlbuterol Sulfate65$4,055
Wixela InhubFluticasone Propion/Salmeterol25$3,345
Prednisone296$817
Doxycycline Hyclate73$463
Fluticasone Propionate12$349
Montelukast Sodium31$319

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$705$359,025612 claims
Boehringer IngelheimCombivent Respimat, Stiolto Respimat$534$28,80943 claims
AstraZenecaBreztri Aerosphere, Symbicort$212$23,91552 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 215 pulmonary disease providers in Alabama.

Other pulmonary disease in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →